Core Viewpoint - Bio-Rad Laboratories, Inc. is set to release its third-quarter 2024 results on October 30, with expectations of mixed performance due to various market challenges and product demand dynamics [1]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for revenues in Q3 2024 is $639.9 million, reflecting a 0.8% increase from the previous year [2]. - The Zacks Consensus Estimate for EPS is $1.28, indicating a significant year-over-year decline of 45.1% [2]. - The earnings estimate has decreased by 40.2% over the past 30 days [3]. Group 2: Factors Affecting Performance - Weakness in the biotech and biopharma markets has negatively impacted sales of Life Science tools and bioprocessing products, with particular challenges in China [4]. - The process chromatography segment is expected to see a sales decline due to ongoing destocking trends in the industry [4]. - In Asia, constrained funding in Japan and soft government spending on life science research are likely to have hindered growth [4]. Group 3: Positive Developments - Despite the challenges, there is demand for the Droplet Digital PCR (ddPCR) platform, particularly in oncology and cell and gene therapy markets [5]. - The launch of new life science platforms, including the ChemiDoc Imaging Systems and a cost-effective single-cell sample prep solution, is expected to positively impact Q3 performance [5]. - The Clinical Diagnostics segment is projected to see a revenue increase of 41.9% year over year to $267.6 million, driven by demand for quality control immunohematology and blood typing products [6]. Group 4: Segment Revenue Projections - The Clinical Diagnostics segment is expected to grow, with revenues projected to increase 57.9% year over year to $369.7 million [7].

Core Insights - BIO-key International, Inc. will sponsor, speak, and exhibit at ISC2 Security Congress 2024, focusing on Passkeys and zero trust concepts in cybersecurity [1][3] - The company emphasizes its unique phoneless, tokenless, and passwordless biometric authentication solutions, which address the needs of enterprise users in phone-free environments [2][5] Company Overview - BIO-key provides innovative identity and access management (IAM) solutions, securing access for over 35 million users with a focus on biometric authentication [6] - The company's PortalGuard® platform helps organizations balance risk, flexibility, and productivity for users and identity administrators [2][6] Event Details - ISC2 Security Congress 2024 is themed "Boldly Forward" and aims to inspire cybersecurity professionals to enhance their skills and strategies [3] - BIO-key will host a session titled "Introducing Passkey:YOU – a Passwordless Authentication Solution that Checks All the Boxes" on October 14, 2024 [4] Product Highlights - The new offering, Passkey:YOU, provides a secure authentication experience without the need for phones or hardware tokens, reducing total cost of ownership [2][5] - The integration of passkeys and biometric authentication is expected to accelerate zero trust strategies for enterprises [5]

Core Insights - Bio-Rad Laboratories, Inc. is well-positioned in the growing digital PCR market with its QX600 Droplet Digital PCR platform, while its clinical diagnostics business is gaining momentum and expanding into new molecular diagnostics areas [1][4] - The company has faced challenges in its Biopharma segment and margin performance due to economic pressures [1][12] Group 1: Company Performance - Bio-Rad's shares have decreased by 4.8% over the past year, contrasting with the industry's growth of 24.7% and the S&P 500's rise of 33.7% [2] - The company has a market capitalization of $893.9 million and has surpassed earnings estimates in three of the last four quarters, with an average surprise of 4.1% [2] Group 2: Key Drivers - The QX600 Droplet ddPCR platform is robust and growing, with a focus on biopharma and new product development in cell biology [4] - Bio-Rad is advancing its strategy through agreements with Allegheny Health Network and Oncocyte Corporation, enhancing its clinical diagnostic applications [5] - The clinical diagnostics segment is experiencing growth, particularly in the diabetes franchise and immunohematology, with new product launches like the IH-500 instrument [6][7] Group 3: International Expansion - Bio-Rad operates in over 35 countries, with optimism about market conditions improving in late 2024 and into 2025 despite current softness in the APAC region [8][9] Group 4: Challenges - The Biopharma segment has shown weakness since 2023, linked to funding constraints in the pharmaceutical industry, impacting sales in Asia [10][11] - Economic factors such as inflation and increased costs have pressured Bio-Rad's margins, with a noted unfavorable product mix affecting gross margins [12] Group 5: Financial Estimates - The Zacks Consensus Estimate for Bio-Rad's 2024 earnings per share remains at $10.31, while revenue estimates are projected at $2.59 billion, indicating a 3% decline from the previous year [13]

Core Insights - Bio-Techne Corporation will showcase its neuroscience research solutions at the Society for Neuroscience annual meeting from October 5-9, 2024, in Chicago, Illinois [1][5] - The company will present a range of high-quality life science reagents, immunoassays, automated proteomic instruments, and multiomics solutions aimed at enhancing research efficiency [2][5] Product Highlights - At booth 1165, Bio-Techne will feature technologies that streamline biomarker discovery, optimize neural cell cultures, and transform drug discovery processes [2] - The company will discuss a study on senescence in the aging brain using the RNAscope™ Multiomic LS assay for high-throughput spatial analysis [3] - A Product Theater presentation will focus on intracellular signaling in Alzheimer's disease, utilizing Simple Western™ technology for protein characterization [4] Presentations and Posters - Bio-Techne will host several presentations, including a discussion on intracellular signaling in Alzheimer's disease and a study on senescence in the aging brain [6][7] - The company will present posters on various topics, including an automated assay for quantifying pTau217 and visualizing neurexin and neuroligin interactions [6][7] Company Overview - Bio-Techne Corporation is a global life sciences company with approximately $1.2 billion in net sales for fiscal 2024 and around 3,100 employees [7]

VANCOUVER, British Columbia and HOLMDEL, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, announced that its long-time customer, the province of British Columbia, has placed new orders with BIO-key. 10,000 users will be added to their existing deploy ...

MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate cultur ...

HOLMDEL, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, today announced it has entered into a warrant inducement agreement with an existing institutional investor for the immediate exercise of certain outstanding warrants that the Company issued on ...

Core Insights - BIO-key International, Inc. has received over $500K in new orders from a respected government defense ministry for its biometric user authentication solution under a three-year purchasing agreement [1][2][4] - The defense ministry is expanding the deployment of BIO-key's solution to over 33,000 users, indicating a growing interest in biometric authentication within the defense sector [2][4] - BIO-key's platform has been integrated with the ministry's virtual desktop infrastructure, allowing secure biometric authentication without the need for phones or tokens [3][4] Company Overview - BIO-key specializes in identity and access management (IAM) solutions that utilize Identity-Bound Biometrics (IBB) for secure, phoneless, tokenless, and passwordless authentication [1][4] - The company has a history of providing secure solutions across various highly-regulated industries, including government, defense, finance, and retail [4] - BIO-key's IAM software secures access for over 35 million users, offering a range of authentication factors tailored to diverse use cases [4]

MINNEAPOLIS, Aug. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM EDT 2024 Wells Fargo Healthcare Conference September 6, 2024 11:00 AM EDT Baird 2024 Global Healthcare Conference September 10, 2024 1:25 PM EDT A live webcast of the presentations can be accessed via the IR Calendar page o ...

HOLMDEL, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and token-less Identity-Bound Biometrics (IBB) authentication solutions, will participate at H.C. Wainwright's 26th Annual Hybrid Global Investment Conference September 9th and 10th. BIO-key's CEO Mike DePasquale will be available for virtual meetings on Monday and Tuesday, September 9th ...